A point mutation in 1 LMNA allele abolishing the ZMP-STE24 recognition site in prelamin A (L647R) causes a mild progeroid disorder with features of mandibuloacral dysplasia. 8 The mutation in LMNA that underlies HGPS (G608G) activates a cryptic RNA splice donor site, leading to an internal deletion of 50 amino acids from prelamin A, including the ZMPSTE24 recognition site. This truncated, permanently farnesylated prelamin A variant is called progerin. Many lines of evidence indicate that it is the dose-dependent presence of farnesylated prelamin A variants in HGPS, restrictive dermopathy, and mandibuloacral dysplasia and not the lack of lamin A that causes progeroid disorders. 1, 6, 7 Investigators have generated several mouse models to study prelamin A processing and disease. These include mice with germline deletion of Zmpste24, which accumulate prelamin A and develop systemic features of progeria, 9,10 and mice with a mutant Lmna allele (∆50) that express progerin and exhibits systemic progeroid features. 11 Neither of these mice develops the profound CVD seen in children with HGPS possibly because they die too early from other problems. Nonetheless, Fong and Young 11, 12 used these strains in pioneering research to show that treatment with protein farnesyltransferase inhibitors ameliorate the progeroid phenotypes, establishing the critical role of permanently farnesylated prelamin A variants in pathogenesis.
More recent mouse models of HGPS in which Lmna splicing is altered exhibit some but not all of the vascular pathology of the disease. Transgenic mice with a bacterial artificial chromosome containing human LMNA engineered to contain the G608G mutation lack most systemic features of progeria but exhibit loss of smooth muscle cells and collagen deposition in the media of the aorta. 13 Mice with a homozygous Lmna G609G mutation, which corresponds to the human LMNA G608G mutation that causes altered RNA splicing, similarly have loss of vascular smooth muscle cells in the aortic arch, as well as systemic features of progeria.
14 Another strain of mice Lmna G609G/G609G develop near complete loss of smooth muscle cells in the media of the ascending aorta as well as advanced adventitial fibrosis by 4 months of age. 15 Taken together, it appears that the predominant common pathological characteristics of the large vessels in children with HGPS and mouse models of the disease are marked loss of vascular smooth muscle cells and arterial adventitial thickening and fibrosis, more severe than that typically observed in the atherosclerosis of physiological aging. 4 In contrast to humans with HGPS, where early onset aggressive atherosclerosis occurs, none of the previous mouse progeria models with defects in prelamin A processing develop all of the features of atherosclerosis, particularly accumulation of lipids and lipid-laden macrophages within the intima of the vessel wall. This difference is likely because the mouse, as a species, is highly resistant to atherosclerosis. Only mice with genetic defects in lipid metabolism, such as Apoe -/-mice 
Lmna
G609G/G609G mice had the same short lifespan as Apoe
, demonstrating that accelerated atherosclerosis does not hasten death and Lmna G609G/G609G mice apparently die from other systemic progeroid defects caused by the ubiquitous expression of progerin. This is in sharp contrast to children with HGPS, with only a heterozygous LMNA mutation, who also express progerin ubiquitously but generally succumb to myocardial infarction and stroke resulting from atherosclerosis.
To circumvent the systemic effects of ubiquitous progerin overexpression, Hamczyk et al 5 also generated a mouse with vascular smooth muscle cell-restricted progerin expression. To do so, they started with mice having a conditional mutant Lmna G609G allele.
14 By crossing these mice to an appropriate Cre driver line and then to Apoe -/-mice, the authors created strains expressing progerin selectively in vascular smooth muscle cells. Satisfyingly, the Apoe -/-
G609/G609 mice exhibited accelerated atherosclerosis independent of other systemic progeroid symptoms and died prematurely, likely because of the sequelae of atherosclerosis. The atheromata in these mice had features of vulnerable plaque, and some data, although not quite conclusive, suggested that they suffered from myocardial infarctions. Thus, these mice may provide a useful preclinical model to study atherosclerosis-associated premature death in children with progeria and possibly more generally. Mice generated by similar methods expressing progerin selectively in macrophages rather than smooth muscle cells did not have accelerated atherosclerosis. Furthermore, mice expressing progerin in vascular smooth muscle cells on the Apoe +/+ background also had loss of these cells and aortic adventitial thickening but did not develop atherosclerosis and had a lifespan similar to that of Apoe +/+ mice. Thus, combining the Apoe -/-and HGPS (Lmna G609G/G609G
) mouse models and restricting progerin expression to vascular smooth muscle cells were the critical innovations in this study that allowed these investigators to develop a novel model for studying the role of vascular smooth muscle cells in driving atherosclerosis.
It is important to point out that the results of Hamczyk et al 5 are reminiscent of past research showing that chronic apoptosis of vascular smooth muscle cells accelerates atherosclerosis in Apoe -/-mice. 17 This finding suggests that most or all of the effects of progerin on atherosclerosis observed in the current experiments are a result of the previously described vascular smooth muscle cell loss in mice expressing this prelamin A variant. However, understanding precisely how progerin promotes vascular smooth muscle cell loss remains to be determined and may provide an important link between lamin A processing and the atherosclerosis occurring in progeria.
HGPS is a monogenic disease with progeroid defects beyond just early onset CVD. Do studies on mouse models of this extraordinarily rare syndrome with features of accelerated aging provide any information relevant to the extraordinarily common atherosclerosis seen with physiological aging? Sporadic use of the same cryptic splice site in LMNA that is activated in HGPS leads to low levels of progerin expression in all individuals. 18 One study has suggested that low levels of progerin can be detected in coronary arteries of individuals without HGPS and that the quantity increases with age. 4 Similarly, prelamin A is normally expressed, albeit transiently, in nearly all cells, and perturbations of ZMPSTE24-catalyzed processing could lead to its accumulation. Indeed, it has been reported that unprocessed prelamin A accumulates in vascular smooth muscle cells in human arteries and atherosclerotic lesions of old individuals and that vascular smooth muscle cells passaged in vitro accumulate prelamin A because of decreased expression or activity of ZMPSTE24. 19 Hence, one could hypothesize that farnesylated prelamin A or its farnesylated variant progerin may function in atherosclerosis of physiological aging perhaps by causing vascular smooth muscle cell loss in a species-humans-that is not as resistant to atherosclerosis as mice. Should further research prove this hypothesis true, treatment with drugs that target farnesylated prelamin A or progerin, such as those used in genetically modified mice with alterations in prelamin A processing or in children with progeria, 10, 11, 13, 14 may someday be used to help prevent atherosclerosis that occurs with physiological aging. 
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